Finance

Lists
Q1 2027 earnings • released • EPS beat +၀.၇၂% • Revenue beat +၃.၀၀%
See results
GLAXO:NSE
GlaxoSmithKline Pharmaceuticals Ltd
၂,၆၄၁.၅၀ ₹
-၀.၇၈%
(-၂၀.၈၀) 1D
ဩ ၄, GMT+၅:၃၀ ၁၅:၃၀:၀၀  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLAXO...
Open
၂,၆၈၀.၂၀ ₹
High
၂,၆၈၄.၀၀ ₹
Low
၂,၆၀၁.၃၀ ₹
Mkt. cap
ဋေ ၄.၄၈ သ
Avg. vol.
၈.၃၃ သောင်း
Volume
၉.၉၇ သောင်း
Dividend
၂.၁၆%
Quarterly dividend
၁၄.၂၅ ₹
Ex-dividend date
၂၀၂၆ မေ ၂၉
P/E ratio
၄၃.၁၉
52-wk high
၂,၉၃၆.၀၀ ₹
52-wk low
၂,၀၈၈.၁၀ ₹
EPS
၆၁.၁၅ ₹
Shares outstanding
၁၆.၉၄ ကုဋေ
No. of employees
၃ ထောင်
Open
၂,၆၈၀.၂၀ ₹
High
၂,၆၈၄.၀၀ ₹
Low
၂,၆၀၁.၃၀ ₹
Mkt. cap
ဋေ ၄.၄၈ သ
Avg. vol.
၈.၃၃ သောင်း
Volume
၉.၉၇ သောင်း
Dividend
၂.၁၆%
Quarterly dividend
၁၄.၂၅ ₹
Ex-dividend date
၂၀၂၆ မေ ၂၉
P/E ratio
၄၃.၁၉
52-wk high
၂,၉၃၆.၀၀ ₹
52-wk low
၂,၀၈၈.၁၀ ₹
EPS
၆၁.၁၅ ₹
Shares outstanding
၁၆.၉၄ ကုဋေ
No. of employees
၃ ထောင်
News stories
From sources across the web
Investor's Business Daily
Investor's Business Daily
·
ပြီးခဲ့သည့် ၄၃ မိနစ်
Dow Jones Futures: S&P 500 Jumps To High; SpaceX, AMD Lead Earnings Movers Late
FinancialContent
FinancialContent
·
ပြီးခဲ့သည့် ၁၆ မိနစ်
Toast (NYSE:TOST) Surprises With Q2 CY2026 Sales
CBS News
CBS News
·
ပြီးခဲ့သည့် ၃ နာရီ
Dow soars 900 points on strong corporate earnings and hopes of Iran deal
Profile
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia
About GlaxoSmithKline Pharmaceuticals Ltd
CEO-
Employees၃.၁ ထောင်
Founded၁၉၂၄ နို ၁၃
Headquarters-
Sector-
Last report
၂၀၂၆ ဩ ၃
Fiscal period
Q1 2027
EPS / Est. (INR)
၁၄.၀၀ ₹ / ၁၃.၉၀ ₹
+၀.၇၂%beat
Revenue / Est. (INR)
၉၃၈.၄၄ ဋေ / ၉၁၁.၁၅ ဋေ
+၃.၀၀%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
၂၀၂၅ ဇွန်
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
Revenue
၈၀၅.၁၇ ဋေ
၉၇၉.၉၄ ဋေ
ဋေ ၁.၀၄ ထ
၉၉၅.၃၀ ဋေ
Cost of goods sold
၂၈၇.၇၁ ဋေ
၃၅၅.၅၃ ဋေ
၃၆၃.၈၂ ဋေ
၃၆၈.၅၆ ဋေ
Cost of revenue
၂၈၇.၇၁ ဋေ
၃၅၅.၅၃ ဋေ
၃၆၃.၈၂ ဋေ
၃၆၈.၅၆ ဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁၅၂.၅၇ ဋေ
၁၃၈.၀၅ ဋေ
၁၅၁.၈၈ ဋေ
၂၉၄.၆၈ ဋေ
Operating expense
၂၈၁.၇၈ ဋေ
၃၀၆.၁၁ ဋေ
၃၂၆.၄၂ ဋေ
၂၈၄.၁၇ ဋေ
Total operating expenses
၅၆၉.၄၉ ဋေ
၆၆၁.၆၄ ဋေ
၆၉၀.၂၄ ဋေ
၆၅၂.၇၃ ဋေ
Operating income
၂၃၅.၆၈ ဋေ
၃၁၈.၃၀ ဋေ
၃၅၁.၀၂ ဋေ
၃၄၂.၅၇ ဋေ
Other non operating income
၄၃.၇၂ ကုဋေ
၃၃.၅၇ ကုဋေ
၃၂.၁၂ ကုဋေ
-၁၀၉.၄၁ ဋေ
EBT including unusual items
၂၇၈.၉၈ ဋေ
၃၅၄.၀၀ ဋေ
၃၉၉.၉၃ ဋေ
၃၇၃.၁၀ ဋေ
EBT excluding unusual items
၂၇၈.၉၈ ဋေ
၃၅၁.၃၆ ဋေ
၃၈၁.၉၅ ဋေ
၂၉၃.၅၁ ဋေ
Income tax expense
၇၃.၉၇ ကုဋေ
၉၆.၅၁ ကုဋေ
၁၀၄.၃၁ ဋေ
၉၅.၂၄ ကုဋေ
Effective tax rate
၂၆.၅၁%
၂၇.၂၆%
၂၆.၀၈%
၂၅.၅၃%
Other operating expenses
၁၁၃.၆၉ ဋေ
၁၅၀.၆၃ ဋေ
၁၅၄.၂၂ ဋေ
-၂၃.၆၈ ကုဋေ
Net income
၂၀၅.၀၁ ဋေ
၂၅၇.၄၉ ဋေ
၂၉၅.၆၂ ဋေ
၂၇၇.၈၆ ဋေ
Net profit margin
၂၅.၄၆%
၂၆.၂၈%
၂၈.၃၉%
၂၇.၉၂%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
၆၅.၇၃ ကုဋေ
Interest expense
-၄.၂၀ သန်း
-၅.၁၀ သန်း
-၁.၁၉ ကုဋေ
-၆.၁၂ သန်း
Net interest expenses
-၄.၂၀ သန်း
-၅.၁၀ သန်း
-၁.၁၉ ကုဋေ
၆၅.၁၂ ကုဋေ
Depreciation and amortization charges
၁၅.၅၂ ကုဋေ
၁၇.၄၃ ကုဋေ
၂၀.၃၂ ကုဋေ
၁၃.၁၇ ကုဋေ
EBITDA
၂၄၅.၂၇ ဋေ
၃၃၄.၇၈ ဋေ
၃၆၀.၆၁ ဋေ
၃၅၂.၁၉ ဋေ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
Google အက်ပ်များ